Geriatric Anorexia Study 2.0

NCT ID: NCT05211973

Last Updated: 2022-09-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

44 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-28

Study Completion Date

2022-09-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Reduction in appetite and/or food intake among older individuals is referred to as anorexia of aging (AOA, also known as Geriatric Anorexia). AOA is linked with myriad comorbidities associated with aging, contributes significantly to adverse health consequences in old age, and has been used as a predictor of morbidity and mortality. The overall aim of this study is to compare feasibility of body weight, body fat, body composition and activity assessments in elderly subjects in long-term care (LTC), nursing home, or assisted living facilities. This will be accomplished through the use of questionnaires in addition to devices that evaluate movement, body composition, and body weight.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall aim of this study is to compare feasibility of body weight, body fat, body composition and activity assessments in elderly subjects in long-term care (LTC), nursing home, or assisted living facilities. This will be accomplished through the use of questionnaires in addition to devices that evaluate movement, body composition, and body weight.

The proposed study will consist of an initial intake visit on Day 1, followed by an at-home (i.e. LTC facility, nursing home, and/or assisted living facility) phase where the participant will wear two watch like devices one on each wrist and answer two questions on paper each day. There will be a second visit on day 8 where the participant will complete additional questionnaires and assessments. The participant will continue wearing the wrist-worn devices for days 9-14, with a final visit on day 15 for final assessments and device collection. A window of +/- 3 days will be allocated for the scheduling of all visits to accommodate participant's schedules and commitments. Activities will take place in the care facility where the participant resides, or the Laboratory for Human Neurobiology for those that will commute. The study procedures will be identical for all participants for all Frailty groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Frailty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fried Frailty Phenotype 0

Those who are considered Robust under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.

Wrist Actigraphy Device

Intervention Type DEVICE

a watch like wearable sensor

Smart Body Weight Scale

Intervention Type DEVICE

a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Chair Scale

Intervention Type DEVICE

a wheel-chair compatible scale to measure body weight

Handheld Body Fat Percentage Device

Intervention Type DEVICE

a handheld device that measures body fat percentage

Bioelectric Impedance Analysis Scale

Intervention Type DEVICE

a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Fried Frailty Phenotype 1-2

Those who are considered Intermediate/Pre-frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.

Wrist Actigraphy Device

Intervention Type DEVICE

a watch like wearable sensor

Smart Body Weight Scale

Intervention Type DEVICE

a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Chair Scale

Intervention Type DEVICE

a wheel-chair compatible scale to measure body weight

Handheld Body Fat Percentage Device

Intervention Type DEVICE

a handheld device that measures body fat percentage

Bioelectric Impedance Analysis Scale

Intervention Type DEVICE

a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Fried Frailty Phenotype 3+

Those who are considered Frail under the Fried Frailty Criteria. Sensor technology and digital measures will be used to evaluate movement and body weight composition in healthy adults.

Wrist Actigraphy Device

Intervention Type DEVICE

a watch like wearable sensor

Smart Body Weight Scale

Intervention Type DEVICE

a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Chair Scale

Intervention Type DEVICE

a wheel-chair compatible scale to measure body weight

Handheld Body Fat Percentage Device

Intervention Type DEVICE

a handheld device that measures body fat percentage

Bioelectric Impedance Analysis Scale

Intervention Type DEVICE

a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Wrist Actigraphy Device

a watch like wearable sensor

Intervention Type DEVICE

Smart Body Weight Scale

a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Intervention Type DEVICE

Chair Scale

a wheel-chair compatible scale to measure body weight

Intervention Type DEVICE

Handheld Body Fat Percentage Device

a handheld device that measures body fat percentage

Intervention Type DEVICE

Bioelectric Impedance Analysis Scale

a research-grade full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends (conducted based on participant's abilities)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Geneactiv Watch Renpho Meilestone Omron Tanita

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female participants aged 65 years of age and over
2. No recent hospitalizations/acute events in last 30 days
3. No active or recent (within 12 months) cancer diagnosis except skin cancer \[limited to only non-complicated squamous and basal cell skin cancer (SCC/BCC)\]
4. Body mass index (BMI) \< 30 kg/m2
5. Able to understand and cooperate with study procedures and able to read, understand and provide informed consent. Evidence of a personally signed and dated informed consent document indicating that the participant, if necessary, their legally authorized representative (LAR) has been informed of all pertinent aspects of the study.
6. Native English speakers or demonstrated fluency in English as determined by the Investigator
7. WRAT-4 Word Reading Subtest equivalent to 8th grade reading level or greater
8. Montreal Cognitive Assessment (MoCA) score of ≥ to 19

Exclusion Criteria

1. Treatment with an investigational drug within 30 days of enrollment
2. Moderate to severe alcohol use disorder diagnosis within 6 months of the screening as disclosed by the subject
3. Participants who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Boston University/Boston Medical Center (BU/BMC) employees directly involved in the conduct of the study
4. Inability to comply with study requirements
5. Life expectancy of less than 6 months, or actively enrolled in a palliative care program
6. Has any clinically significant medical disorder, condition, disease, or clinically significant finding at screening that precludes subject's participation in study activities
7. Participants with electronic implant such as pacemaker etc., due to Bioelectric Impedance Analysis (BIA) body composition devices (Tanita, Smart body scale) using tiny electrical signal for measurements
8. At an increased risk of COVID-19 as determined by the Laboratory for Human Neurobiology COVID-19 Human Subject Risk Assessment Survey
9. Temperature equal to or above 100.4 degrees F
10. Modified Barthel Index of \<40
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kevin C Thomas, PhD, MBA

Role: PRINCIPAL_INVESTIGATOR

Principal Investigator, Boston University, Department of Anatomy & Neurobiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Evans Biomedical Research Center

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-42048

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.